In the US, an observational study9 using Medicare fee-for-service claims from 73 475 beneficiaries who were newly diagnosed with AD found no difference in skilled nursing facility admissions among cholinesterase inhibitor initiators, memantine initiators, and combination therapy initiators. This evidence concerns the gene BCHE and Alzheimer disease.